Report Publication Announcement • Oct 23, 2020
Report Publication Announcement
Open in ViewerOpens in native device viewer
BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020
Bergen, Norway, 23[rd] October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, is pleased to announce that it will
host a virtual R&D Day on 06 November 2020 from 13.00 CET.
The event will feature independent experts highlighting the role of AXL kinase
as an essential mediator of the biological mechanisms underlying life
-threatening diseases. The presentations will focus on the role of AXL in
specific disease areas including oncology, fibrosis and infectious disease such
as COVID-19. Each presentation will be followed by a Q&A session.
A preliminary program for the event is outlined below. To register, please click
here (bergenbio@consilium
-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20E
vent).
Preliminary Agenda
(times in CET)
13:00 Introduction - Richard
Godfrey, Chief Executive
Officer, BerGenBio
13:10 AXL in AML/MDS
- Professor Sonja
Loges, Director,
Department
of Personalised Oncology,
University Hospital
Mannheim and Division
of Personalised Medical
Oncology, German Research
Center - DKFZ
(Heidelberg, Germany)
13:40 AXL in lung cancer - Dr
Matthew Krebs, Clinical
Senior Lecturer in
Experimental Cancer
Medicine and Honorary
Consultant in Medical
Oncology, The Christie
NHS Foundation Trust
(Manchester, UK)
14:10 AXL and viruses/COVID-19
- Professor Wendy Maury,
Professor of Microbiology
and Immunology,
University of Iowa (Iowa
City, USA)
14:40 AXL in fibrosis/IPF -
Professor Cory Hogaboam,
Professor of Medicine,
Cedars-Sinai Medical
Center (Los Angeles, USA)
15:10 Bemcentinib clinical
development plan - Hani
Gabra, Chief Medical
Officer, BerGenBio
15:25 Concluding remarks -
Richard Godfrey, Chief
Executive Officer,
BerGenBio
For further information, please contact Consilium
Strategic Communications at bergenbio@consilium
-comms.com or
i ([email protected])[email protected] ([email protected])m
- END -
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body's immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.